Weifeng Wang1, Shaohua Peng2, Huanliang Wu2, Yunxiu Luo2, Feng Yuan3, Zhiren Lin3, Gang Cheng3, Shengmin Chen3. 1. Department of Oncology Radiotherapy, Hainan Cancer Hospital, 4 th west Street of ChangBin Road, Haikou, 570311, China. wangwf0912@163.com. 2. Department of Oncology Radiotherapy, Hainan Cancer Hospital, 4 th west Street of ChangBin Road, Haikou, 570311, China. 3. Department of Radiation Oncology, Haikou Municipal Hospital, Haikou, China.
Abstract
PURPOSE: Assessing the downstaging effects of neoadjuvant chemotherapy (NACT) in patients with locally advanced nasopharyngeal carcinoma (LANPC) and predicting response to treatment remain challenging. The present study aimed to evaluate the long-term prognosis of downstaging after NACT in patients with LANPC and to investigate the prognostic value of post-NACT tumor downstaging on treatment outcomes in the era of concurrent chemoradiotherapy (CCRT). METHODS: This retrospective study included 226 patients with stage III (n = 188) and IVA (n = 38) NPC admitted to Haikou People's Hospital between 1 October 2009 and 1 October 2012. The patients were grouped as downstaging or no after NACT. Overall survival (OS), locoregional failure-free survival (LFFS), and distant failure-free survival (DFFS) were analyzed. RESULTS: Among 226 patients, 196 (86.7%) were in the downstaging group and 30 (13.3%) were in the non-downstaging group. The longest follow-up was 76 months, and the median was 45 months. The 3-year OS rates of the downstaging group and non-downstaging group were 91.0% (95% CI 0.89-0.93) and 69.5% (95% CI 0.66-0.72) (P = 0.005). The 5-year OS rates were 81.6% (95% CI 0.78-0.86) and 53.3% (95% CI 0.49-0.61) (P = 0.001). N downstaging (3-year OS, HR 0.491, 95% CI 0.221-0.881, P = 0.022; 5-year OS, HR = 0.597, 95% CI 0.378-0.878, P = 0.021) was independently associated with OS. CONCLUSION: In the treatment of LANPC, the patients with downstaging after NACT have a better prognosis than those without downstaging. This study suggests that NACT can improve the prognosis for patients with LANPC if there is downstaging.
PURPOSE: Assessing the downstaging effects of neoadjuvant chemotherapy (NACT) in patients with locally advanced nasopharyngeal carcinoma (LANPC) and predicting response to treatment remain challenging. The present study aimed to evaluate the long-term prognosis of downstaging after NACT in patients with LANPC and to investigate the prognostic value of post-NACT tumor downstaging on treatment outcomes in the era of concurrent chemoradiotherapy (CCRT). METHODS: This retrospective study included 226 patients with stage III (n = 188) and IVA (n = 38) NPC admitted to Haikou People's Hospital between 1 October 2009 and 1 October 2012. The patients were grouped as downstaging or no after NACT. Overall survival (OS), locoregional failure-free survival (LFFS), and distant failure-free survival (DFFS) were analyzed. RESULTS: Among 226 patients, 196 (86.7%) were in the downstaging group and 30 (13.3%) were in the non-downstaging group. The longest follow-up was 76 months, and the median was 45 months. The 3-year OS rates of the downstaging group and non-downstaging group were 91.0% (95% CI 0.89-0.93) and 69.5% (95% CI 0.66-0.72) (P = 0.005). The 5-year OS rates were 81.6% (95% CI 0.78-0.86) and 53.3% (95% CI 0.49-0.61) (P = 0.001). N downstaging (3-year OS, HR 0.491, 95% CI 0.221-0.881, P = 0.022; 5-year OS, HR = 0.597, 95% CI 0.378-0.878, P = 0.021) was independently associated with OS. CONCLUSION: In the treatment of LANPC, the patients with downstaging after NACT have a better prognosis than those without downstaging. This study suggests that NACT can improve the prognosis for patients with LANPC if there is downstaging.
Authors: Yu-Pei Chen; Nofisat Ismaila; Melvin L K Chua; A Dimitrios Colevas; Robert Haddad; Shao Hui Huang; Joseph T S Wee; Alexander C Whitley; Jun-Lin Yi; Sue S Yom; Anthony T C Chan; Chao-Su Hu; Jin-Yi Lang; Quynh-Thu Le; Anne W M Lee; Nancy Lee; Jin-Ching Lin; Brigette Ma; Thomas J Morgan; Jatin Shah; Ying Sun; Jun Ma Journal: J Clin Oncol Date: 2021-01-06 Impact factor: 44.544
Authors: Andrew R Davies; James A Gossage; Janine Zylstra; Fredrik Mattsson; Jesper Lagergren; Nick Maisey; Elizabeth C Smyth; David Cunningham; William H Allum; Robert C Mason Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Anne W Lee; Wai Tong Ng; Jian Ji Pan; Sharon S Poh; Yong Chan Ahn; Hussain AlHussain; June Corry; Cai Grau; Vincent Grégoire; Kevin J Harrington; Chao Su Hu; Dora L Kwong; Johannes A Langendijk; Quynh Thu Le; Nancy Y Lee; Jin Ching Lin; Tai Xiang Lu; William M Mendenhall; Brian O'Sullivan; Enis Ozyar; Lester J Peters; David I Rosenthal; Yoke Lim Soong; Yungan Tao; Sue S Yom; Joseph T Wee Journal: Radiother Oncol Date: 2017-11-15 Impact factor: 6.280